• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖皮质激素受体与乳腺癌。

Glucocorticoid receptor and breast cancer.

机构信息

INSERM-UPMC, UMRS 938, Hôpital Saint-Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France.

出版信息

Breast Cancer Res Treat. 2011 Nov;130(1):1-10. doi: 10.1007/s10549-011-1689-6. Epub 2011 Aug 5.

DOI:10.1007/s10549-011-1689-6
PMID:21818591
Abstract

Stress enhances glucocorticoid (GC) synthesis, which alters inflammation and immune responses, as well as cellular proliferation and apoptosis in a number of tissues. Increasingly, stress has been associated with cancer progression, and in particular in breast cancer. Consequently, an operational glucocorticoid receptor system in breast tissue influences breast cancer development. In this review, we summarize the data on the GC/GR system in normal and tumoral breast tissue. We also review the molecular mechanisms by which GCs control apoptosis and proliferation in breast cancer models and how GCs alter the chemotherapy of breast cancer treatment when used in combination. Finally, we discuss the participation of GR in breast tumorigenesis under hormone replacement therapy.

摘要

压力会增强糖皮质激素(GC)的合成,从而改变许多组织中的炎症和免疫反应,以及细胞增殖和凋亡。越来越多的证据表明,压力与癌症的进展有关,尤其是乳腺癌。因此,乳腺组织中功能性糖皮质激素受体系统会影响乳腺癌的发展。在这篇综述中,我们总结了 GC/GR 系统在正常和肿瘤乳腺组织中的数据。我们还回顾了 GCs 通过何种分子机制控制乳腺癌模型中的细胞凋亡和增殖,以及当与化疗联合使用时 GCs 如何改变乳腺癌治疗的化疗效果。最后,我们讨论了在激素替代疗法下 GR 参与乳腺肿瘤发生的情况。

相似文献

1
Glucocorticoid receptor and breast cancer.糖皮质激素受体与乳腺癌。
Breast Cancer Res Treat. 2011 Nov;130(1):1-10. doi: 10.1007/s10549-011-1689-6. Epub 2011 Aug 5.
2
Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.糖皮质激素受体活性可区分孕激素和醋酸甲羟孕酮在乳腺细胞中的作用。
Breast Cancer Res Treat. 2012 Jan;131(1):49-63. doi: 10.1007/s10549-011-1394-5. Epub 2011 Feb 19.
3
Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.雌激素受体、孕激素受体和糖皮质激素受体在正常乳腺组织、乳腺原位癌和浸润性乳腺癌中的表达。
Appl Immunohistochem Mol Morphol. 2010 May;18(3):254-7. doi: 10.1097/PAI.0b013e3181c10180.
4
Progesterone, glucocorticoid, but not estrogen receptor mRNA is altered in breast cancer stroma.乳腺癌基质中孕激素、糖皮质激素受体mRNA发生改变,但雌激素受体mRNA未改变。
Cancer Lett. 2007 Sep 18;255(1):77-84. doi: 10.1016/j.canlet.2007.03.019. Epub 2007 May 23.
5
Glucocorticoid receptor signaling and prostate cancer.糖皮质激素受体信号与前列腺癌。
Cancer Lett. 2011 Mar 1;302(1):1-10. doi: 10.1016/j.canlet.2010.10.020.
6
Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.孕激素诱导的人乳腺癌消退中的雌激素、雄激素、糖皮质激素和孕激素受体
Cancer Res. 1980 Jul;40(7):2557-61.
7
Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer.
J Exp Clin Cancer Res. 1997 Mar;16(1):95-103.
8
[Hormonal and genotoxic aspects of BRCA1-associated carcinogenesis].
Vopr Onkol. 2007;53(6):642-53.
9
The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.刚性甾体 21-羟基-6,19-环氧黄体酮(21OH-6,19OP)是一种分离的糖皮质激素受体调节剂,可能作为乳腺癌化疗的新型辅助药物具有应用价值。
Biochem Pharmacol. 2014 Jun 15;89(4):526-35. doi: 10.1016/j.bcp.2014.04.006. Epub 2014 Apr 13.
10
[Hormone dependence and the basis of hormone therapy in breast cancer].[激素依赖性与乳腺癌激素治疗的基础]
J Gynecol Obstet Biol Reprod (Paris). 1978 Mar;7(2):183-99.

引用本文的文献

1
Evaluation of the Safety and Antiproliferative Activity of Bulgarian Rose Essential Oil: An In Vitro and In Silico Model of Colorectal Adenocarcinoma.保加利亚玫瑰精油的安全性和抗增殖活性评估:结直肠癌的体外和计算机模拟模型
Curr Issues Mol Biol. 2025 Aug 13;47(8):649. doi: 10.3390/cimb47080649.
2
Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.源自一个南美国家的乳腺癌患者来源异种移植瘤的类固醇激素受体、外显子组测序与治疗反应性
Sci Rep. 2025 Jan 18;15(1):2415. doi: 10.1038/s41598-025-86389-x.
3
Enhancing the Inhibition of Breast Cancer Growth Through Synergistic Modulation of the Tumor Microenvironment Using Combined Nano-Delivery Systems.
通过联合纳米递药系统协同调节肿瘤微环境增强乳腺癌生长抑制作用。
Int J Nanomedicine. 2024 Jun 4;19:5125-5138. doi: 10.2147/IJN.S460874. eCollection 2024.
4
Prognostic Value of SGK1 and Bcl-2 in Invasive Breast Cancer.SGK1和Bcl-2在浸润性乳腺癌中的预后价值
Cancers (Basel). 2023 Jun 11;15(12):3151. doi: 10.3390/cancers15123151.
5
MDM2- an indispensable player in tumorigenesis.MDM2- 肿瘤发生中不可或缺的参与者。
Mol Biol Rep. 2023 Aug;50(8):6871-6883. doi: 10.1007/s11033-023-08512-3. Epub 2023 Jun 14.
6
Choosing the right partner in hormone-dependent gene regulation: Glucocorticoid and progesterone receptors crosstalk in breast cancer cells.选择正确的激素依赖性基因调控伙伴:糖皮质激素和孕激素受体在乳腺癌细胞中的相互作用。
Front Endocrinol (Lausanne). 2022 Nov 4;13:1037177. doi: 10.3389/fendo.2022.1037177. eCollection 2022.
7
Surgical Stress and Cancer Progression: New Findings and Future Perspectives.手术应激与癌症进展:新发现与未来展望。
Curr Oncol Rep. 2022 Nov;24(11):1501-1511. doi: 10.1007/s11912-022-01298-w. Epub 2022 Jun 28.
8
Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression.糖皮质激素在乳腺癌进展中具有上下文相关作用的机制。
Cancer Metastasis Rev. 2022 Dec;41(4):803-832. doi: 10.1007/s10555-022-10047-1. Epub 2022 Jun 27.
9
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.乳腺癌中拉帕替尼靶向抗HER2/ErbB2治疗耐药:攻克难题的机遇
Cancer Drug Resist. 2020 Feb 28;3(2):179-198. doi: 10.20517/cdr.2019.92. eCollection 2020.
10
Comprehensive analysis of FKBP4/NR3C1/TMEM173 signaling pathway in triple-negative breast cancer cell and dendritic cell among tumor microenvironment.肿瘤微环境中三阴性乳腺癌细胞与树突状细胞内FKBP4/NR3C1/TMEM173信号通路的综合分析
Mol Ther Oncolytics. 2022 Jan 4;24:371-384. doi: 10.1016/j.omto.2021.12.024. eCollection 2022 Mar 17.